| ABVC BioPharma is a clinical stage biopharmaceutical company. Co.'s wholly owned subsidiaries, American BriVision Corporation, focuses on the development of ABV-1701 Vitreous Substitute for Vitrectomy. Through its another wholly owned subsidiary, BioLite Holding Inc., Co. conducts clinical research and trials of various drug candidates, including: ABV-1504 for the treatment of Major Depressive Disorder, ABV-1505 to treat Attention-Deficit Hyperactivity Disease, ABV-1501 for the treatment of Triple Negative Breast Cancer, ABV-1703 for the treatment of Pancreatic Cancer, ABV-1702 to treat Myelodysplastic syndromes and ABV-1601 Depression in Cancer Patients. We show 12 historical shares outstanding datapoints in our coverage of ABVC's shares outstanding history.
Understanding the changing numbers of ABVC shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ABVC versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ABVC by allowing them to research ABVC shares outstanding history
as well as any other stock in our coverage universe.